Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience

被引：0
作者：
Lorenzo Livi
Pierluigi Bonomo
Icro Meattini
Gabriele Simontacchi
Daniela Greto
Isacco Desideri
Fiammetta Meacci
Vieri Scotti
Sara Cecchini
Jacopo Nori
Luis Jose Sanchez
Lorenzo Orzalesi
Fabiola Paiar
Gianpaolo Biti
机构：
[1] University of Florence,Radiotherapy Unit, IFCA
[2] University of Florence,Radiation Oncology Department, AOUC
[3] University of Florence,Diagnostic Senology Unit
[4] University of Florence,Department of Surgery
来源：
Medical Oncology | 2013年 / 30卷
关键词：
Breast cancer; Metastatic breast carcinoma; Bevacizumab; Paclitaxel; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The aim of our analysis was to report the outcome and safety of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2-negative metastatic breast cancer. Between February 2009 and August 2011, 62 consecutive patients received paclitaxel 90 mg/m2 on days 1, 8, and 15 and bevacizumab (BV) 10 mg/kg intravenously on days 1 and 15, every 28-day cycle. After 6 cycles of combined treatment, patients were given maintenance BV every 3 weeks (15 mg/kg) until progression disease or unacceptable toxicity. At time of analysis, median overall survival was 12.3 months (range 4.6–44.8 months), progression-free survival was 8.1 months (range 2.3–33.2 months), and time to treatment failure was 8.4 months (range 2.3–33.2 months). Our results confirmed the efficacy and the acceptable toxicity profile of bevacizumab plus paclitaxel as first-line regimen for metastatic breast cancer.
引用
收藏
相关论文
共 50 条
  • [1] Miller K(2007)Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666-2676
  • [2] Wang M(2010)Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 3229-3247
  • [3] Gralow J(2011)RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 1252-1260
  • [4] Miles DW(2010)Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controller trials Oncologist 15 1179-1191
  • [5] Chan A(2011)First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients Ann Oncol 22 595-602
  • [6] Dirix LY(2005)A systematic review of taxane-containing regimens for metastatic breast cancer Br J Cancer 93 293-301
  • [7] Robert NJ(1996)The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res 2 1843-1849
  • [8] Dieras V(2001)The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res 61 3369-3372
  • [9] Glaspy J(2010)Bevacizumab improves the delivery and efficacy of paclitaxel Anticancer Drugs 21 687-694
  • [10] Geiger-Gritsch S(2010)Bevacizumab in combination with taxanes for the first line treatment of metastatic breast cancer Ann Oncol 21 2305-2315
12345